Latest & greatest articles for sofosbuvir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sofosbuvir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sofosbuvir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sofosbuvir

21. [Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to õ35a Social Code Book V]

[Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to õ35a Social Code Book V] Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55 [Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to §35a Social Code Book V] Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55 [Sofosbuvir (hepatitis C in adolescents) - benefit (...) assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55

Health Technology Assessment (HTA) Database.2018

22. sofosbuvir velpatasvir voxilaprevir (TBC)

sofosbuvir velpatasvir voxilaprevir (TBC) sofosbuvir velpatasvir voxilaprevir | CADTH.ca Find the information you need sofosbuvir velpatasvir voxilaprevir Generic Name: sofosbuvir velpatasvir voxilaprevir Brand Name: TBC Manufacturer: Gilead Sciences Canada, Inc. Indications: Hepatitis C, chronic Submission Type: New Combination Project Status: Pending Call For Patient Input: July 7, 2017 Patient Input Closed: August 28, 2017 Anticipated Date: August 4, 2017 Biosimilar: No Fee Schedule 1

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2018

23. Sofosbuvir/velpatasvir for hepatitis C virus infection

Sofosbuvir/velpatasvir for hepatitis C virus infection Sofosbuvir/velpatasvir for hepatitis C virus infection | RADAR 20 Years Of Helping Australians Make Better Decisions About Medicines, Medical Tests And Other Health Technologies. Log in Facebook Twitter LinkedIn Google Signing you in Use another account OR Login Form Email Password Log in to NPS MedicineWise Don't have an account? Forgot password Forgot password Email Send reset instructions Set new password Reset Password Password Set (...) the and accept the Subscribe Breadcrumbs Sofosbuvir/velpatasvir for hepatitis C virus infection Article Sections Sofosbuvir/velpatasvir for hepatitis C virus infection 25 Oct 2017 4 min read Share Share to: Print Larger text Smaller text Sofosbuvir/velpatasvir (400 mg/100 mg) fixed dose combination (FDC) (Epclusa) is a pan-genotypic DAA. Sofosbuvir is an inhibitor of HCV NS5B nucleotide polymerase, essential for viral replication. Velpatasvir is an inhibitor of NS5A, essential for both RNA replication

National Prescribing Service Limited (Australia)2018

24. Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) ? Benefit assessment according to §35a Social Code Book V

Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.9 of the dossier assessment Sofosbuvir/Velpatasvir/Voxilaprevir (chronische Hepatitis C) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A17-35 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-35 Version 1.0 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

25. Ledipasvir/sofosbuvir (hepatitis C) ? Benefit assessment according to §35a Social Code Book V

Ledipasvir/sofosbuvir (hepatitis C) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A17-41 Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-41 Version 1.0 Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) – Benefit

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

26. Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus‐related cirrhosis

Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus‐related cirrhosis Sofosbuvir Induced Steven Johnson Syndrome in a Patient With Hepatitis C Virus-Related Cirrhosis Nipun Verma , 1 Shreya Singh, 2 Gitesh Sawatkar, 3 and Virendra Singh 1 Sofosbuvir is an imperative drug used in treatment regimens for hepatitis C virus (HCV). It is considered relatively safe with fewer adverse effects than other treatments. Here, we report a rare and potentially serious (...) , dermatologic, adverse effect following the use of sofosbuvir. A 35-year-old man with genotype 3-related HCV cirrhosis presented with decom- pensated ascites and jaundice following 7 weeks of therapy with peginterferon alpha-2a and oral ribavirin. After peginter- feron withdrawal and stabilization, oral sofosbuvir and ribavirin were started; 10 days later, he developed itching over the trunk and legs, followed by multiple papules and vesicles over an erythematous base. Over the next 15 days, the rash pro

Hepatology communications2017 Full Text: Link to full Text with Trip Pro

28. Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) - To treat adults with chronic hepatitis C virus

Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) - To treat adults with chronic hepatitis C virus Drug Approval Package: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) Company: Gilead Sciences, Inc. Application No.: 209195Orig1s000 Approval Date: July 18, 2017 Persons with disabilities having problems accessing the PDF files below may call (301

FDA - Drug Approval Package2017

29. Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V

Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V Extract 1 Translation of Sections 2.1 to 2.13 of the dossier assessment Sofosbuvir/Velpatasvir (chronische Hepatitis C) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 October 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission (...) No. A16-48 Sofosbuvir/velpatasvir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A16-48 Version 1.0 Sofosbuvir/velpatasvir (chronic hepatitis C) 13 October 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V Commissioning agency

Institute for Quality and Efficiency in Healthcare (IQWiG)2017

30. Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48

Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48 1 Translation of addendum A16-73 Sofosbuvir/Velpatasvir (chronische Hepatitis C) – Addendum zum Auftrag A16-48 (Version 1.0; Status: 8 December 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 8 December 2016 1.0 Commission: A16-73 Version: Status: IQWiG Reports (...) – Commission No. A16-73 Sofosbuvir/velpatasvir (chronic hepatitis C) – Addendum to Commission A16-48 1 Addendum A16-73 Version 1.0 Sofosbuvir/velpatasvir – Addendum to Commission A16-48 8 December 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir (chronic hepatitis C) – Addendum to Commission A16-48 Commissioning agency: Federal Joint Committee Commission awarded on: 23

Institute for Quality and Efficiency in Healthcare (IQWiG)2017

31. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. BACKGROUND: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS: We conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 infection (...) who had previously received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive either the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks. Patients who were infected with HCV of other genotypes (114 patients) were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group. In POLARIS-4, patients with HCV genotype 1, 2

NEJM2017

32. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C 28660147 2018 11 13 2225-0719 5 2 2017 Jun 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. 101-108 10.14218/JCTH.2016.00070 Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal (...) and associated with significant morbidity and mortality. Methods: We retrospectively evaluated the safety and efficacy of ledipasvir/sofosbuvir with and without ribavirin in LT recipients with recurrent genotype 1 hepatitis C. Results: Eighty-five LT recipients were treated for recurrent HCV with ledipasvir/sofosbuvirwith and without ribavirin for 12 or 24 weeks. The mean (± standard deviation [SD]) time from LT to treatment initiation was 68 (±71) months. The mean (± SD) age of the cohort was 63 (±8.6

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

33. Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen 29270489 2018 11 13 2468-0249 2 5 2017 Sep Kidney international reports Kidney Int Rep Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. 831-835 10.1016/j.ekir.2017.04.003 There is paucity of data on sofosubvir (SOF)-based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy (...) Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India. Bagchi Soumita S Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India. Yadav Raj Kumar RK Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India. eng Journal Article 2017 04 26 United States Kidney Int Rep 101684752 2468-0249 DAA HCV India daclatasvir hemodialysis sofosbuvir 2017 01 25 2017 04 06 2017 04 11 2017 12 23 6 0 2017 12 23 6 0 2017 12 23 6 1 epublish

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

34. Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience

Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience 28507922 2018 11 13 2225-0719 5 1 2017 Mar 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience. 23-26 10.14218/JCTH.2016.00060 Background and Aims: Patients with chronic hepatitis C (CHC) and end-stage renal disease (ESRD) who are dialysis-dependent form a unique group, in which safety, tolerability (...) and efficacy of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) need further evaluation. Methods: We performed a retrospective analysis of 14 patients with CHC and ESRD on dialysis who received 15 courses of SOF-based therapy. We evaluated dose escalation to standard-dose SOF in this proof-of-principle experience. Results: Sustained virological response (defined as undetectable viral load at 12 weeks, SVR-12) was achieved in 13 out of the 15 (86.7%) treatment courses. Seven (46.6%) patients received

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

35. Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States 28507921 2018 11 13 2225-0719 5 1 2017 Mar 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. 16-22 10.14218/JCTH.2016.00052 Background and Aims: The current paradigm of specialist physician-managed treatment of chronic

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

36. Sofosbuvir-velpatasvir for chronic HCV infection

Sofosbuvir-velpatasvir for chronic HCV infection Sofosbuvir-velpatasvir for chronic HCV infection Sofosbuvir-velpatasvir for chronic HCV infection HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Sofosbuvir-velpatasvir for chronic HCV infection. Lansdale: HAYES, Inc. Directory Publication. 2016 Authors' objectives Sofosbuvir-velpatasvir (...) (Epclusa) is a "next-generation" once-daily direct-acting antiretroviral (DAA) combination oral regimen for the treatment of all 6 major hepatitis C virus (HCV) genotypes. The fixed-dose combination pill contains 400 mg of sofosbuvir and 100 mg of velpatasvir. Rationale: Sofosbuvir-velpatasvir is intended to treat any genotype and subtype of HCV using an existing drug with accepted efficacy, plus a new drug that is intended to improve efficacy by targeting HCV in a different way. Relevant Questions

Health Technology Assessment (HTA) Database.2017

37. [Sofosbuvir/velpatasvir (chronic hepatitis C) - benefit assessment according to õ35a SGB V]

[Sofosbuvir/velpatasvir (chronic hepatitis C) - benefit assessment according to õ35a SGB V] Sofosbuvir/celpatasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertungen; auftrag A16-48 [Sofosbuvir/velpatasvir (chronic hepatitis C) - benefit assessment according to §35a SGB V] Sofosbuvir/celpatasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertungen; auftrag A16-48 [Sofosbuvir/velpatasvir (chronic hepatitis C) - benefit assessment according (...) to §35a SGB V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sofosbuvir/celpatasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertungen; auftrag A16-48. [Sofosbuvir

Health Technology Assessment (HTA) Database.2017

38. Sofosbuvir?velpatasvir for treating chronic hepatitis C

Sofosbuvir?velpatasvir for treating chronic hepatitis C Sofosbuvir–v Sofosbuvir–velpatasvir for treating elpatasvir for treating chronic hepatitis C chronic hepatitis C T echnology appraisal guidance Published: 25 January 2017 nice.org.uk/guidance/ta430 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 31Contents Contents 1 Recommendations 4 2 The technology 6 3 Evidence 7 4 Committee

National Institute for Health and Clinical Excellence - Technology Appraisals2017

39. Adverse effects of pseudoephedrine and sofosbuvir

Adverse effects of pseudoephedrine and sofosbuvir Prescrire IN ENGLISH - Spotlight ''In the January issue of Prescrire International: adverse effects of pseudoephedrine and sofosbuvir'', 1 January 2017 {1} {1} {1} | | > > > In the January issue of Prescrire International: adverse effects of pseudoephedrine and sofosbuvir Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |  (...)  |  Spotlight In the January issue of Prescrire International: adverse effects of pseudoephedrine and sofosbuvir FREE DOWNLOAD In the "Adverse Effects" section of this month's issue, ischaemic colitis with the decongestant pseudoephedrine, and a risk of pulmonary arterial hypertension with the hepatitis C drug sofosbuvir. Full text available for free download. Pseudoephedrine: ischaemic colitis Sympathomimetic vasoconstrictors can provoke neurological and cardiovascular adverse effects

Prescrire2017

40. EPCLUSA (sofosbuvir/velpatasvir), fixed combination of direct-acting antivirals

EPCLUSA (sofosbuvir/velpatasvir), fixed combination of direct-acting antivirals Haute Autorité de Santé - EPCLUSA (sofosbuvir/velpatasvir), association fixe d’antiviraux à action directe Contribuer à la régulation par la qualité et l'efficience Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments EPCLUSA (sofosbuvir/velpatasvir), association fixe d’antiviraux à action directe Substance active (DCI) sofosbuvir (...) est importante, avec une durée de traitement de 12 semaines pour l’ensemble des patients (avec ou sans cirrhose), contrairement aux alternatives disponibles qui nécessitent le plus souvent l’ajout de ribavirine et/ou une prolongation de la durée de traitement jusqu’à 24 semaines en cas de cirrhose compliquée ou d’antécédent de traitement. Son efficacité est supérieure à celle de l’association sofosbuvir + ribavirine pour le génotype 2, mais n’est pas optimale pour le génotype 3. Son profil de

Haute Autorite de sante2017